ABOUT US
Mission Statement
We Save Babies.
Quality is the key to our success. We focus on safety, performance, and customer service to meet your needs. We maintain our quality management system by complying with applicable regulatory requirements.
We Save Babies.
Quality is the key to our success. We focus on safety, performance, and customer service to meet your needs. We maintain our quality management system by complying with applicable regulatory requirements.
Company Profile
Our Company
We provide inspired infant care with our revolutionary LifePulse® Ventilator, the first high-frequency ventilator ever approved for clinical use (1988).
Established in 1980, Bunnell has focused its efforts on the development of advanced ventilation systems for treating premature infants in acute respiratory failure, an often fatal complication of preterm birth. The Company manufactures, markets, and services its products for hospitals in the United States, Canada, Australia, and Malaysia. Since its introduction, the LifePulse® Ventilator has helped health care professionals save approximately 100,000 infants.
Our Mission
We Save Babies. Bunnell's continuing mission is to be the preferred, worldwide provider of ventilation products and services used by health care professionals in the treatment of critically ill children.
For over 30 years Bunnell has devoted a portion of its revenues to the development of new, leading-edge technologies for the treatment of critically ill infants and children. In 1995, following a development program supported by the National Institutes of Health (NIH), the Company introduced the LifePort™ endotracheal tube adapter. This device allows clinicians to implement treatment with the Life Pulse system more quickly without reintubation, a potentially traumatic procedure for these fragile patients. The "WhisperJet" patient box reduces noise associated with HFJV by as much as 75%.
Clinical investigation continues with the use of the LifePulse® Ventilator for the treatment of a variety of infant respiratory diseases. Bunnell has sponsored two major multi-center clinical trials where the LifePulse® has been compared with conventional ventilation for the treatment of respiratory distress syndrome and pulmonary interstitial emphysema in premature infants. Respiratory distress syndrome is the leading cause of chronic lung disease, brain injury and death in newborn infants. Bunnell's clinical investigators and trainers are constantly seeking ways to improve the outcome of ventilator therapy.
Our products are manufactured in our Salt Lake City facility and distributed directly to client hospitals. We provide 24-hour, 7-day per week technical and clinical assistance to health care providers including emergency delivery of our life-saving products to hospitals throughout the United States, usually within 2-4 hours of a clinician's request.
Our Commitment
We are committed to providing our life-saving products and services at a standard of quality, performance, and value that exceeds the expectations of our hospital and health care customers.
Our Company
We provide inspired infant care with our revolutionary LifePulse® Ventilator, the first high-frequency ventilator ever approved for clinical use (1988).
Established in 1980, Bunnell has focused its efforts on the development of advanced ventilation systems for treating premature infants in acute respiratory failure, an often fatal complication of preterm birth. The Company manufactures, markets, and services its products for hospitals in the United States, Canada, Australia, and Malaysia. Since its introduction, the LifePulse® Ventilator has helped health care professionals save approximately 100,000 infants.
Our Mission
We Save Babies. Bunnell's continuing mission is to be the preferred, worldwide provider of ventilation products and services used by health care professionals in the treatment of critically ill children.
For over 30 years Bunnell has devoted a portion of its revenues to the development of new, leading-edge technologies for the treatment of critically ill infants and children. In 1995, following a development program supported by the National Institutes of Health (NIH), the Company introduced the LifePort™ endotracheal tube adapter. This device allows clinicians to implement treatment with the Life Pulse system more quickly without reintubation, a potentially traumatic procedure for these fragile patients. The "WhisperJet" patient box reduces noise associated with HFJV by as much as 75%.
Clinical investigation continues with the use of the LifePulse® Ventilator for the treatment of a variety of infant respiratory diseases. Bunnell has sponsored two major multi-center clinical trials where the LifePulse® has been compared with conventional ventilation for the treatment of respiratory distress syndrome and pulmonary interstitial emphysema in premature infants. Respiratory distress syndrome is the leading cause of chronic lung disease, brain injury and death in newborn infants. Bunnell's clinical investigators and trainers are constantly seeking ways to improve the outcome of ventilator therapy.
Our products are manufactured in our Salt Lake City facility and distributed directly to client hospitals. We provide 24-hour, 7-day per week technical and clinical assistance to health care providers including emergency delivery of our life-saving products to hospitals throughout the United States, usually within 2-4 hours of a clinician's request.
Our Commitment
We are committed to providing our life-saving products and services at a standard of quality, performance, and value that exceeds the expectations of our hospital and health care customers.
Our Founder
|
Bert Bunnell, ScD, began searching for a better way of breathing for premature babies in 1972. His hard work and dedication led to the development of the LifePulse® High Frequency Ventilator. To learn more about this incredible journey, read Bert's Bio and a Student Essay about Bert and the LifePulse®.
|
Call The Hotline: 800-800-4358